55 Everolimus with Reduced CsA vs MMF with Standard CsA Exposure in De Novo Heart Transplant Recipients: 12 Month Efficacy and Safety Analysis

Journal article

Peer reviewed

H. Eisen, D. Pauly, R. Starling, H. Lehmkuhl, H. Ross, A. Kfoury, S. Wang, B. Cantin, A. Van Bakel, A. Zuckermann, …

The Journal of heart and lung transplantation, v 30(4), pp S25-S26

2011

Additional Links

9 Record Views

Title: 55 Everolimus with Reduced CsA vs MMF with Standard CsA Exposure in De Novo Heart Transplant Recipients: 12 Month Efficacy and Safety Analysis
Creators: H. Eisen - Drexel University
D. Pauly - Florida College
R. Starling - Cleveland Clinic
H. Lehmkuhl - Deutsches Herzzentrum der Charité
H. Ross - University Health Network
A. Kfoury - Intermountain Medical Center
S. Wang - National Taiwan University
B. Cantin - Université Laval
A. Van Bakel - Medical University of South Carolina
A. Zuckermann - University of Vienna
P. Lopez - Novartis (Switzerland)
G. Dong - Novartis (Switzerland)
C. Panis - Novartis (Switzerland)
H. Jiang - Novartis (Switzerland)
C. Cornu-Artis - Novartis (Switzerland)
J. Kobashigawa - Cedars-Sinai Smidt Heart Institute
Publication Details: The Journal of heart and lung transplantation, v 30(4), pp S25-S26
Publisher: Elsevier
Resource Type: Journal article
Language: English
Web of Science ID: WOS:000288924300056
Other Identifier: 991019335239504721

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Web of Science research areas: Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation